Drug introduction:
Temozolomide is a new anticancer drug produced by Schering-Plough Company, which is used to treat glioma and malignant melanoma. It is the first compound of a new substance called imidazole tetrazine. Because of its low toxicity and good tolerance, this oral cytotoxic alkylating agent has taken an important step in the treatment of glioma. It can be completely absorbed after oral administration, with high bioavailability and good tissue distribution, and can penetrate the blood-brain barrier. The main side effects are moderate nausea, vomiting, fatigue, constipation and moderate myelosuppression, which can be recovered and controlled by conventional methods. Because of its small toxic and side effects, it can be used for a long time, which improves the long-term curative effect, obviously improves the physical and mental state of patients and improves the quality of life of patients. Temozolomide is still effective after resistance to conventional chemotherapy (BCNU, CCNU). These two drugs not only have no cross resistance but also have synergistic effect. It can prolong the progression-free survival of these patients, which is longer than the standard treatment of procarbazide. Therefore, temozolomide is the best drug to treat glioma and malignant melanoma.
Drug price:
5 mg *20 capsules = $380.
20 mg *20 capsules = 1250 USD.
100
Mg*5 capsules = 1280 USD.
Current domestic retail price: 50mg * 7: 2600 yuan/bottle (one-time purchase of more than 3 bottles 10% discount), 5mg * 8: 246 yuan/bottle.